DHG Pharmaceutical : Annual Report 2022 DHG Pharma

DHG PHARMACEUTICAL JOINT STOCK COMPANY

TICKER SYMBOL: DHG

ANNUAL REPORT

2022

1/43

THEME OF THE ANNUAL REPORT 2022

........................................................................................

LIST OF ABBREVIATIONS

2/43

OVERVIEW OF THE COMPANY

3/43

CONTENTS OF THE ANNUAL REPORT 2022

MESSAGE FROM THE BOD CHAIRWOMAN

CHAPTER 1: OVERVIEW OF DHG PHARMA

1. Vision - Mission - Core Values
2. Financial highlights in 2018 - 2022
3. Distinguished awards in 2022
4. Historical milestones
5. The secret of success 2020 - 2022
6. Business lines and market regions
7. Corporate model
8. Organizational apparatus
9. Board profile

CHAPTER 2: DEVELOPMENT STRATEGIES

1. Macroenvironment and Vietnam pharmaceutical industry
2. S.W.O.T analysis
3. Short, medium and long-term development strategies

4/43

MESSAGE FROM THE CHAIRWOMAN OF THE BOARD OF DIRECTORS

Dear valued shareholders, partners, customers and all employees!

A year has passed with the witness of the slowing down of the global economy, but DHG Pharma has managed to overcome difficulties to maintain and develop positively its business activities. The leading position that DHG Pharma has achieved is convincingly demonstrated in many aspects, from business strategy to the expansion of its development scale, from achievements to values, not just numbers that reflect its growing heat.

In 2022, DHG Pharma recorded its highest sales and profit rates in its 48-year history of development with:

• Net sales: VND 4,676 billion, up 16.8% compared to 2021.
• Profit after tax: VND 988 billion, up 27.3% compared to 2021.

DHG Pharma successfully maintained its leading position in Vietnam's pharmaceutical industry for 26 consecutive years and Top 5 pharmaceutical companies with the largest market share in Vietnam's pharmaceutical industry (according to IQVIA's statistics in the 4th quarter of 2022).

To accomplish these impressive business results, DHG Pharma has flexibly applied its reasonable business strategies and actively exploited the inherent potentials from its strengths, experiences, and widespread distribution system. However, since the economy and society are always changing, so are the needs of the market and customers, in order to be faster, more efficient and stronger, DHG Pharma must be more stable and flexible in all circumstances to continue to reach further. Being fully aware of that, DHG Pharma always considers what is achieved as an encouragement to continue to lift up its development speed in the coming years.

Ladies and gentlemen!

In 2022, DHG Pharma marked the expansion of development scale and enhanced its product quality with the official starting of the construction of a Betalactam factory that meets Japan/EU_GMP standards. This project has significant importance for the plan to develop high-quality product lines, providing consumers with many qualified product lines that replace foreign drugs. With the addition of a Betalactam factory meeting Japan/EU_GMP standards, DHG Pharma has increased its competitiveness in the domestic pharmaceutical market, not only solidly maintaining its No.1 position in Vietnam but also confidently stepping in the world pharmaceutical market. This competitive advantage also contributes to the development of the country's pharmaceutical industry on the world map.

5/43